AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$RLAY

Rahmer Peter sold $90K of RLAY

Rahmer Peter (See remarks) sold 4,508 shares of Relay Therapeutics, Inc. (RLAY) at $20.03 on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rahmer Peter
Published Aug 28, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLAY
Neutral
high confidence
Mentioned
$RLAY
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYNeutralLow
01

Why it matters

The modest sale is unlikely to affect RLAY's stock price materially.

02

Market read

Routine insider sale with minimal trading relevance.

03

What to watch

Potential upcoming clinical trial results not disclosed in filing.

Relevance 2/10Novelty 2/10Timing: filed post‑market on 2026‑08‑28

Background

Form 4 filing reports insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$RLAYNeutralHigh confidence
Context

Officer Rahmer Peter sold 4,508 shares of Relay Therapeutics for $90,295 via a 10b5‑1 plan.

Expected impact

No significant price change expected.

Evidence & confidence

The sale size is small relative to market cap and typical insider activity.

Market effects

Sector

Limited impact on biotech sector; insider sales are routine.

Regional

No regional effect.

Global

Not globally relevant.

Counterpoint

What could challenge this read

If the insider is reducing exposure, it could signal concerns about upcoming data.

Key entities

  • Company
    Relay Therapeutics, Inc.

    Biotech firm developing precision medicines.

  • Officer
    Rahmer Peter

    Insider officer executing a pre‑arranged 10b5‑1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLAY insider trading history →

Related articles

AUG 6
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K6 min
JUN 2
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com1 min